US20220002226A1 - Amorphous Form of Chelating Agents and Process for Preparing them - Google Patents
Amorphous Form of Chelating Agents and Process for Preparing them Download PDFInfo
- Publication number
- US20220002226A1 US20220002226A1 US17/281,732 US201917281732A US2022002226A1 US 20220002226 A1 US20220002226 A1 US 20220002226A1 US 201917281732 A US201917281732 A US 201917281732A US 2022002226 A1 US2022002226 A1 US 2022002226A1
- Authority
- US
- United States
- Prior art keywords
- acid
- edta
- chelating agent
- amorphous form
- edetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002738 chelating agent Substances 0.000 title claims abstract description 103
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 73
- 229960001484 edetic acid Drugs 0.000 claims abstract description 59
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000000243 solution Substances 0.000 claims abstract description 47
- 229960003330 pentetic acid Drugs 0.000 claims abstract description 26
- 239000002904 solvent Substances 0.000 claims abstract description 26
- 238000001035 drying Methods 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000002253 acid Substances 0.000 claims abstract description 18
- VKZRWSNIWNFCIQ-WDSKDSINSA-N (2s)-2-[2-[[(1s)-1,2-dicarboxyethyl]amino]ethylamino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NCCN[C@H](C(O)=O)CC(O)=O VKZRWSNIWNFCIQ-WDSKDSINSA-N 0.000 claims abstract description 12
- PQHYOGIRXOKOEJ-UHFFFAOYSA-N 2-(1,2-dicarboxyethylamino)butanedioic acid Chemical compound OC(=O)CC(C(O)=O)NC(C(O)=O)CC(O)=O PQHYOGIRXOKOEJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940120146 EDTMP Drugs 0.000 claims abstract description 12
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims abstract description 12
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 150000007513 acids Chemical class 0.000 claims abstract description 12
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims abstract description 6
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 claims abstract description 6
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims abstract description 6
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 claims abstract description 6
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims abstract description 6
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims abstract description 6
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000467 phytic acid Substances 0.000 claims abstract description 6
- 229940068041 phytic acid Drugs 0.000 claims abstract description 6
- 235000002949 phytic acid Nutrition 0.000 claims abstract description 6
- 230000003750 conditioning effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 62
- 238000001694 spray drying Methods 0.000 claims description 53
- 230000008569 process Effects 0.000 claims description 38
- 239000002245 particle Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 14
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- KYQODXQIAJFKPH-UHFFFAOYSA-N diazanium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [NH4+].[NH4+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O KYQODXQIAJFKPH-UHFFFAOYSA-N 0.000 claims description 7
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 claims description 6
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims description 6
- 229940009662 edetate Drugs 0.000 claims description 6
- 229940037001 sodium edetate Drugs 0.000 claims description 6
- 229960005066 trisodium edetate Drugs 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 5
- 229960000074 biopharmaceutical Drugs 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 229910021645 metal ion Inorganic materials 0.000 claims description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229950009719 calcium trisodium pentetate Drugs 0.000 claims description 4
- AYFCVLSUPGCQKD-UHFFFAOYSA-I calcium;trisodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O AYFCVLSUPGCQKD-UHFFFAOYSA-I 0.000 claims description 4
- LQPLDXQVILYOOL-UHFFFAOYSA-I pentasodium;2-[bis[2-[bis(carboxylatomethyl)amino]ethyl]amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC(=O)[O-])CCN(CC([O-])=O)CC([O-])=O LQPLDXQVILYOOL-UHFFFAOYSA-I 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 3
- 239000004568 cement Substances 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000003337 fertilizer Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000004753 textile Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 230000009849 deactivation Effects 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 238000004076 pulp bleaching Methods 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 235000011114 ammonium hydroxide Nutrition 0.000 claims 1
- 229910052925 anhydrite Inorganic materials 0.000 claims 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract description 15
- 235000006408 oxalic acid Nutrition 0.000 abstract description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 238000000634 powder X-ray diffraction Methods 0.000 description 17
- 239000007921 spray Substances 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000007789 gas Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000000889 atomisation Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 230000002572 peristaltic effect Effects 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- 239000007962 solid dispersion Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000005595 deprotonation Effects 0.000 description 2
- 238000010537 deprotonation reaction Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012633 leachable Substances 0.000 description 2
- 239000010808 liquid waste Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005979 thermal decomposition reaction Methods 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 1
- XDYSZKZSEFCBRN-UHFFFAOYSA-H O=C(CN(CCN1CC(=O)O[Ca]OC(=O)C1)CC(=O)[Na]O)O[Na].O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O.O=C(O)CN(CCN(CC(=O)O[Na])CC(=O)[Na]O)CC(=O)O Chemical compound O=C(CN(CCN1CC(=O)O[Ca]OC(=O)C1)CC(=O)[Na]O)O[Na].O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CC(=O)O.O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O.O=C(O)CN(CCN(CC(=O)O[Na])CC(=O)[Na]O)CC(=O)O XDYSZKZSEFCBRN-UHFFFAOYSA-H 0.000 description 1
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 1
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 1
- GIEAQDPIWWODTH-UHFFFAOYSA-N [Na].[Na].[Na].[Ca] Chemical compound [Na].[Na].[Na].[Ca] GIEAQDPIWWODTH-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- -1 alkaline earth metal sulphate Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000002655 chelation therapy Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940043353 maltol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000012503 pharmacopoeial method Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002901 radioactive waste Substances 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/38—Separation; Purification; Stabilisation; Use of additives
- C07C227/40—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/76—Metal complexes of amino carboxylic acids
Definitions
- the present invention relates generally to new stable amorphous forms of chelating agents, to compositions and uses thereof, and to a process of producing stable amorphous chelating agents, especially particles thereof. More particularly, it relates to a process for producing amorphous chelating agents by dissolving them in a suitable solvent or mixture of solvents, optionally purifying the solution and isolating particles of essentially amorphous chelating agent by solvent removal, preferably by spray drying. Moreover, the amorphous particulates produced in accordance with the process of present invention present advantageous characteristics regarding particle size batch-to-batch consistency and solubility. These agents can be applied, for example, in the pharmaceutical field particularly in novel formulations having these excipients in the composition.
- Chelating agents are chemical compounds whose structures permit the attachment of their two or more donor atoms (or sites) to a single metal ion simultaneously (Flora et al. 2015). These molecules are also called chelants, chelators or sequestering agents.
- chelating agents are ethylenediaminetetraacetic acid/edetic acid (EDTA), sodium edetate (Na-EDTA), disodium edetate (2Na-EDTA), dipotassium edetate (2K-EDTA), calcium disodium edetate (2NaCa-EDTA), trisodium edetate (3Na-EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), diethylenetriaminepentaacetic acid calcium trisodium (3NaCa-DTPA), nitrilotriacetic acid (NTA), amino tris(methylenephosphonic acid) (ATMP), ethylenediamine tetramethylene phosphonic acid (EDTMP), 1-hydroxyethane 1,1-diphosphonic acid (HEDP), ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (IDS) chitosan, hydroxamic acid, oxalic acid,
- Chelating agents are not only used in industrial and agricultural applications, such as chemical water treatment, fertilizers, paper and textile production, cleaning and laundry operations, prevention/inhibition of the growth of microorganisms, soil remediation, wastes and effluents treatment, metal electroplating and other surface treatments, tanning processes, cement admixtures, photography, food products and cosmetics. They are also used in several medical applications such as chelation therapy to detoxify poisonous metal agents converting them into inert forms, as contrast agents in MRI (Magnetic Resonance Imaging) scanning, as radioisotope chelators and in pharmaceuticals as excipients or processing adjuvants.
- MRI Magnetic Resonance Imaging
- chelating agents can be added to formulations to protect against autoxidation; they act by forming complexes with the heavy metal ions which are often required to initiate oxidative reactions (Loftsson. 2014) and to chelate metal leachables that arise from components and materials used in manufacturing, storage, and delivery of the therapeutic (Zhou et al, 2010).
- Chelating properties have major importance in biopharmaceuticals. Compared to small molecules, proteins in nature exhibit significantly lower stability due to the strong dependence of their physico-chemical properties on their structure and conformation. This and their generally larger-size offer multiple sites for potential interaction with leachables (like metal ions), increasing the risk for degradation and loss of activity.
- the metal chelator disodium EDTA (2Na-EDTA) has been commonly used in parenteral formulations.
- DTPA has also been used in several approved parenteral products (Zhou et al, 2010; FDA Inactive ingredient database).
- Chelating agents such as EDTA and DTPA are soluble in water only at higher pH (around 8) at room temperature which are conditions that could affect the structure and conformation of proteins.
- amorphous forms or amorphous solid dispersions There are several techniques for producing amorphous forms or amorphous solid dispersions namely, but not limited to, freeze-drying, precipitation, melt extrusion and spray-drying.
- Spray drying is a well-established manufacturing technique which can be an effective strategy to deliver poorly water soluble drugs (Singh and Mooter, 2015).
- a typical spray-drying apparatus comprises a drying chamber, atomizing means for atomizing a solvent-containing feed into the drying chamber, a source of heated drying gas that flows into the drying chamber to remove solvent from the atomized-solvent-containing feed and product.
- Spray drying of chelating agents is disclosed in:
- U.S. Pat. No. 4,636,336 which describes a process for reducing the volume of a liquid waste containing an organic amine chelating agent in which a finely atomized spray of liquid waste is contacted with a gas stream having a temperature in excess of thermal decomposition temperature of chelating agent.
- the objective of this process is to reduce the volume of radioactive waste produced and the drying temperature has to be higher than the thermal decomposition temperature of the chelating agent, meaning higher than 200° C. (more precisely 250-400° C.), much higher than the temperatures defined in the present invention (which are 50 to 100° C.).
- WO9929656 A1 where is described a method for producing high purity crystals of tetrasodium salt of ethylenediaminetetraacetic acid (4Na-EDTA).
- 4Na-EDTA ethylenediaminetetraacetic acid
- a crystalline form is produced and those crystals could be recovered by spray drying, consuming organic solvents.
- Solid dispersions of the penta-ethyl ester prodrug of diethylenetriaminepentaacetic acid (DTPA) article describes the incorporation of a prodrug of DTPA into a matrix (Amorphous solid dispersion), by spray-drying. Nevertheless, this is a prodrug of DTPA and a polymer matrix is used to stabilize it (Yang et al., 2014).
- FIG. 1 illustrates the spray-drying set up used
- FIG. 2 illustrates a SEM image of spray dried particles of amorphous DTPA
- FIG. 3 illustrates a XRPD diffractogram of DTPA obtained by spray drying
- FIG. 4 represents SEM image of spray dried particles amorphous EDTA
- FIG. 5 illustrates a XRPD diffractogram of EDTA obtained by spray drying
- FIG. 6 represents SEM image of spray dried particles amorphous diammonium EDTA
- FIG. 7 illustrates a XRPD diffractogram of diammonium EDTA obtained by spray drying
- FIG. 8 represents a SEM image of spray dried particles amorphous 2Na-EDTA
- FIG. 9 illustrates a XRPD diffractogram of 2Na-EDTA obtained by spray drying
- FIG. 10 represents a graphic of crystalline 2Na-EDTA dissolution rate
- FIG. 11 represents a graphic of amorphous 2Na-EDTA dissolution rate.
- the present invention provides novel amorphous solid forms of chelating agents, such as EDTA and DTPA, and a method of preparing those amorphous forms.
- chelating agents such as EDTA and DTPA
- the amorphous chelating agents can be obtained by a simple and industrial method comprising, for example, spray drying of a solution of chelating agents. Due to the spray drying technique used these amorphous forms have also a controlled particle size distribution.
- amorphous chelating agents are provided and are suitable to be used in human and veterinary pharmaceutical applications. In another aspect of this invention, amorphous chelating agents are provided and are suitable to be used in biopharmaceutical formulations as well as pharmaceutical formulations.
- chelating agents such as, but not limited to, ethylenediaminetetraacetic acid/edetic acid (EDTA), diethylenetriamine-pentaacetic acid/pentetic acid (DTPA), nitrilotriacetic acid (NTA), amino tris(methylenephosphonic acid) (ATMP), ethylenediamine tetramethylene phosphonic acid (EDTMP), 1-hydroxyethane 1,1-diphosphonic acid (HEDP), ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (IDS) hydroxamic acid, oxalic acid, galactaric acid, metaphosphoric acid or phytic acid and salts thereof have never been reported to be isolated in a stable amorphous form.
- EDTA ethylenediaminetetraacetic acid/edetic acid
- DTPA diethylenetriamine-pentaacetic acid/pentetic acid
- NTA nitrilotriacetic acid
- ATMP
- an amorphous form of a chelating agent is stable, and may be provided in a “pure” state, without the need for any other compounds to provide stability.
- the amorphous form of a chelating agent is provided in particulate form.
- the chelating agent comprises ethylenediaminetetraacetic acid/edetic acid (EDTA) or a salt thereof, or diethylenetriaminepentaacetic acid/pentetic acid (DTPA), or a salt thereof, although we have found that other chelating agents may also be provided in amorphous form.
- EDTA ethylenediaminetetraacetic acid/edetic acid
- DTPA diethylenetriaminepentaacetic acid/pentetic acid
- the amorphous form is obtained by spray drying, but other suitable techniques may be used.
- the invention thus provides a spray dried amorphous form of a chelating agent.
- a spray dried amorphous form of ethylenediaminetetraacetic acid/edetic acid (EDTA) or a salt thereof, or a spray dried amorphous form of diethylenetriaminepentaacetic acid/pentetic acid (DTPA), or a salt thereof, are particularly preferred.
- the chelating agent may comprise ethylenediaminetetraacetic acid/edetic acid (EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), nitrilotriacetic acid (NTA), amino tris(methylenephosphonic acid) (ATMP), ethylenediamine tetramethylene phosphonic acid (EDTMP), 1-hydroxyethane 1,1-diphosphonic acid (HEDP), ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (IDS), hydroxamic acid, oxalic acid, galactaric acid, metaphosphoric acid, or phytic acid, or a salt of any one or more of the above acids, or a mixture of two or more of any of the above acids or salts thereof.
- EDTA ethylenediaminetetraacetic acid/edetic acid
- DTPA diethylenetriaminepentaacetic acid/pentetic acid
- NTA nitrilotri
- the amorphous form of a chelating agent is in the form of a hydrate, an anhydrate or a solvate.
- an amorphous form of a chelating agent as provided by the invention is free of additives, for example free of metal, or metal containing compounds.
- the chelating agents of the present invention may be provided without the need for any additional compounds or additives to stabilise the amorphous form, and that they are stable.
- the invention thus provides an isolated amorphous form of a chelating agent, free of additives. It also provides an isolated amorphous form of a chelating agent, free of metal or metal-containing compounds, such as metal ions or metal salts.
- an amorphous form of a chelating agent as provided by the invention is free of a support matrix, such as, for example, a polymer matrix.
- a support matrix such as, for example, a polymer matrix.
- the chelating agents of the present invention may be provided without the need for any support matrix to stabilise the amorphous form, and that they are stable.
- the invention thus provides an isolated amorphous form of a chelating agent, free of a support matrix, such as a polymer matrix.
- each amorphous form of a chelating agent as provided by the invention is both free of additives, and also free of a support matrix, such as a polymer matrix.
- an amorphous form of a chelating agent wherein the chelating agent comprises ethylenediaminetetraacetic acid/edetic acid (EDTA), sodium edetate (Na-EDTA), disodium edetate (2Na-EDTA), dipotassium edetate (2K-EDTA), calcium disodium edetate (2NaCa-EDTA), trisodium edetate (3Na-EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), pentasodium pentetate, or calcium trisodium pentetate, or a mixture of two or more of any of the above acids or salts.
- EDTA ethylenediaminetetraacetic acid/edetic acid
- Na-EDTA sodium edetate
- dipotassium edetate (2K-EDTA) calcium disodium edetate
- 3Na-EDTA triso
- the invention also provides an amorphous form of a chelating agent as described above, wherein the solubility in water of the amorphous form is higher than that of the corresponding crystalline form.
- amorphous chelating agents provided by the invention.
- the amorphous chelating agents provided herein also, in general, possess a higher dissolution rate in aqueous media such as water, and this is a further advantage.
- the invention provides a process for preparing an amorphous form of a chelating agent, which process comprises the steps of:
- any suitable chelating agent may be used, but particularly suitable chelating agents include ethylenediaminetetraacetic acid/edetic acid (EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), nitrilotriacetic acid (NTA), amino tris(methylenephosphonic acid) (ATMP), ethylenediamine tetramethylene phosphonic acid (EDTMP), 1-hydroxyethane 1,1-diphosphonic acid (HEDP), ethylenediaminedisuccinic acid (EDDS), iminodisuccinic acid (IDS), hydroxamic acid, oxalic acid, galactaric acid, metaphosphoric acid, or phytic acid, or a salt of any one or more of the above acids, or a mixture of two or more of any of the above acids or salts thereof.
- EDTA ethylenediaminetetraacetic acid/edetic acid
- DTPA diethylenetriaminepentaacetic acid/pentetic acid
- the amorphous form of a chelating agent is in the form of a hydrate, an anhydrate or a solvate.
- the amorphous form produced is preferably free of additives or a support matrix such as a polymer matrix.
- the process of the invention may, in particular, be employed to provide an amorphous form of a chelating agent, wherein the chelating agent comprises ethylenediaminetetraacetic acid/edetic acid (EDTA), sodium edetate (Na-EDTA), disodium edetate (2Na-EDTA), dipotassium edetate (2K-EDTA), calcium disodium edetate (2NaCa-EDTA), trisodium edetate (3Na-EDTA), diethylenetriaminepentaacetic acid/pentetic acid (DTPA), pentasodium pentetate, calcium trisodium pentetate, or a mixture of two or more of any of the above acids or salts.
- EDTA ethylenediaminetetraacetic acid/edetic acid
- Na-EDTA sodium edetate
- 2Na-EDTA disodium edetate
- 2K-EDTA dipotassium edetate
- the present invention thus provides a process for the preparation of amorphous chelating agents comprising the steps of:
- Preparing a solution of chelating agent in step a) comprises the addition of crystalline chelating agent to a suitable solvent. Crystalline forms of the chelating agents may be readily obtained, as will be clear to those skilled in this field.
- the solvent temperature used to prepare a solution of the chelating agent is suitably from about 20° C. to about 60° C.
- the chelating agent can be dissolved in any suitable solvent, and suitable solvents include any solvents that have no adverse effect on the compound and can dissolve the starting material to a useful extent.
- suitable solvents include, but are not limited to: water, aqueous solution of sodium hydroxide, aqueous solution of ammonia, or a mixture of two or more such solvents.
- the solvent may be an organic solvent and may comprise, for example methanol, ethanol, isopropanol, or acetone or a mixtures of two or more such solvents.
- chelating agent concentration may be used, up to the solubility limit. However a solution concentration of from about 0.05% to about 10% w/w is preferred, ideally between 0.5% and 5.0% w/w where “% w/w” refers to the mass of the chelating agent as a percentage of the mass of the total solution. The concentration to be employed will generally be limited by the solubility of the chelating agent in the solvent.
- Step a) may optionally include a purification step of the compound using, for example, a resin, activated charcoal, filtration or other suitable method.
- Step b) involves isolating an amorphous form of the chelating agent from the solution obtained in step a).
- Isolation of the amorphous form of the chelating agent comprises the removal of the solvent by any known technique, such as freeze-drying, vacuum drying or spray-drying, preferably by spray drying.
- step b After step b), optionally, a post drying or conditioning step may be carried out.
- Spray drying may be performed using any suitable or commercially available equipment.
- atomization methods can be used, depending on the equipment chosen. For example, we have found a pneumatic spray nozzle orifice of 1.4 mm is suitable although alternative atomization methods such as two- or three-fluid, rotary, pressure and ultrasonic nozzles may be employed.
- the preferential atomization gas flow in terms of liters per hour can be adjusted to the equipment in use and any suitable atomization gas flow can be used. Typically, for a small scale unit, 150 to 300 milliliters per hour is preferred. In an industrial scale a different flow may be used.
- the nozzle assembly can be cooled with a suitable fluid during spray drying to minimize product degradation.
- the outlet temperature range may be from about 20° C. to about 220° C., preferably from about 40° C. to about 80° C. and more preferably from about 50° C. to about 70° C.
- the inlet temperature may be adjusted to attain the desired outlet temperature.
- the solution flow rate may preferably be from about 1 to about 20 ml/min, more preferably 2 to 15 ml/min for the 1.4 mm nozzle.
- the solution flow rate may be adjusted depending on the selected nozzle.
- the drying gas flow rate for a small scale spray dryer may suitably be from about 20 kg/h to about 120 kg/h, preferably from about 40 kg/h to about 80 kg/h, most preferably about 40 kg/h.
- the drying gas flow rate for a larger spray dryer may, for example, be greater than about 120 kg/h preferably from about 360 kg/h to about 1250 kg/h, for example about 650 kg/h or about 1250 kg/h.
- the outlet temperature, atomization flow rate, solution concentration and solution flow rate, among other tested parameters, can be combined and adjusted to obtain a compound with suitable quality.
- the compounds obtained using the method of this invention are amorphous solids that shows stability over time.
- the process of the invention is carried out such that the amorphous chelating agent particle size distribution is controlled.
- a spray drying technique for solvent evaporation we can adjust the droplet size and solution concentration in order to obtain the desired particle size.
- the range usually defined for this type of drying technique is below about 25 ⁇ m and above 1 ⁇ m of average particle size distribution.
- average particle size distribution ranges of 1-20 ⁇ m, or 2-18 ⁇ m, or 3-15 ⁇ m may be used.
- the invention provides the use of an amorphous chelating agent according to the invention described herein, in a process or composition in the industrial, agricultural or domestic field.
- such use in a process or composition in the industrial, agricultural or domestic field may comprise: pulp bleaching, food and beverage preservation, industrial cleaning, detergents, cement, personal care and cosmetics, fertilizers, water treatment, or removal of and deactivation of metal ions in textiles.
- amorphous chelating agents of the present invention may be used in a conventional way in the pharmaceutical and biopharmaceutical field, in a similar manner to the way conventional chelating agents are used.
- the invention also provides a pharmaceutical or biopharmaceutical composition comprising:
- Example 1, 2, 3 and 4 are set forth to illustrate and aid in understanding the invention but are not intended to, and should not be considered to, limit its scope in any way.
- the experiments reported were carried out using a BUCHI model B-290 advanced spray dryer.
- Example 1 Amorphous DTPA Production by Spray Drying
- DTPA in a mass proportion of 0.5% (w/w), was dissolved in water at 40° C., and stirred until a clear solution was obtained.
- FIG. 1 schematically shows the spray drying set up used.
- the spray drying unit Before feeding the solution to the nozzle, the spray drying unit was stabilized with nitrogen to assure stable inlet (T_in) and outlet temperatures (T_out). After stabilization, the solution was fed to the nozzle by means of a peristaltic pump, and atomized at the tip of the nozzle. The droplets were then dried in the spray drying chamber by current nitrogen. The stream containing the dried particles was directed into a cyclone and collected at the bottom.
- Table 1 The main operating parameters during the spray drying process are summarized in table 1.
- the compound obtained using the method of this invention is an amorphous solid with higher solubility and dissolution rate (in aqueous media) compared with the corresponding crystalline form.
- XRPD x-ray powder diffraction
- DSC differential scanning calorimetry
- the appearance of the atomized material was characterized by means of scanning electron microscopy (SEM). A representative image of the particles obtained is shown in FIG. 2 .
- the X-ray powder diffraction pattern of DTPA obtained by spray drying according to the process herein disclosed is presented in FIG. 3 .
- the XRPD method settings applied for analyzing the sample are given in the table below:
- Anti-scatter slit Programmable anti-scatter slit Detector PIXcel1D-Medipix3 detector Beam attenuator Actual Receiving slit None Measurement parameters Scan axis Gonio Scan mode Continuous Start angle (°): 3.9915 End angle (°): 50.000 Time per step (s): 39.525
- Solubility was assessed using the European Pharmacopeia method referred to above where increasing amounts of water are added to 100 mg of powder until its complete dissolution (or otherwise). According to this method if 100 mg do not solubilize in 30 ml the material is considered insoluble. Nevertheless, in this case, increasing amounts of water were added after 30 ml, in order to identify the actual solubility of the material.
- Example 2 Amorphous EDTA Production by Spray Drying
- EDTA in a mass proportion of 0.05% (w/w), was dissolved in water at 60° C., and stirred until a clear solution was obtained.
- FIG. 1 schematically shows the spray drying set up used.
- the spray drying unit Before feeding the solution to the nozzle, the spray drying unit was stabilized with nitrogen to assure stable inlet (T_in) and outlet temperatures (T_out). After stabilization, the solution was fed to the nozzle by means of a peristaltic pump, and atomized at the tip of the nozzle. The droplets were then dried in the spray drying chamber by co-current nitrogen. The stream containing the dried particles was directed into a cyclone and collected at the bottom.
- T_in stable inlet
- T_out outlet temperatures
- the compound obtained using the method of this invention is an amorphous solid with higher solubility and dissolution rate compared with the corresponding crystalline form.
- XRPD x-ray powder diffraction
- DSC differential scanning calorimetry
- the appearance of the atomized material was characterized by means of scanning electron microscopy (SEM). A representative image of the particles obtained is shown in FIG. 4 .
- the X-ray powder diffraction pattern of EDTA obtained by spray drying according to the process herein disclosed is presented in FIG. 5 .
- the method used to analyze the samples is as described in Example 1.
- Example 3 Amorphous Diammonium EDTA Production by Spray Drying
- EDTA in a mass proportion of 0.5% (w/w), was dissolved in water with 0.4% ammonium hydroxide at 22° C., and stirred until a clear solution was obtained.
- FIG. 1 schematically shows the spray drying set up used.
- the spray drying unit Before feeding the solution to the nozzle, the spray drying unit was stabilized with nitrogen to assure stable inlet (T_in) and outlet temperatures (T_out). After stabilization, the solution was fed to the nozzle by means of a peristaltic pump, and atomized at the tip of the nozzle. The droplets were then dried in the spray drying chamber by co-current nitrogen. The stream containing the dried particles was directed into a cyclone and collected at the bottom.
- T_in stable inlet
- T_out outlet temperatures
- the compound obtained using the method of this invention is an amorphous solid with higher solubility and dissolution rate compared with the corresponding crystalline form.
- XRPD x-ray powder diffraction
- DSC differential scanning calorimetry
- the appearance of the atomized material was characterized by means of scanning electron microscopy (SEM). A representative image of the particles obtained is shown in FIG. 6 .
- the X-ray powder diffraction pattern of diammonium EDTA obtained by spray drying according to the process herein disclosed is presented in FIG. 7 .
- the method used to analyze the samples is as described in Example 1.
- FIG. 1 schematically describes the spray drying set up used.
- the spray drying unit Before feeding the solution to the nozzle, the spray drying unit was stabilized with nitrogen to assure stable inlet (T_in) and outlet temperatures (T_out). After stabilization, the solution was fed to the nozzle by means of a peristaltic pump, and atomized at the tip of the nozzle. The droplets were then dried in the spray drying chamber by co-current nitrogen. The stream containing the dried particles was directed into a cyclone and collected at the bottom. Main operating parameters during the spray drying process are summarized in table 7.
- the compound obtained using the method of this invention is an amorphous solid with higher solubility and dissolution rate compared with the corresponding crystalline form.
- XRPD x-ray powder diffraction
- DSC differential scanning calorimetry
- the appearance of the atomized material was characterized by means of scanning electron microscopy (SEM). A representative image of the particles obtained is shown in FIG. 8 .
- the X-ray powder diffraction pattern of 2Na-EDTA obtained by spray drying according to the process herein disclosed is presented in FIG. 9 .
- the method used to analyze the samples is as described in Example 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Non-Alcoholic Beverages (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PT115056A PT115056B (pt) | 2018-10-04 | 2018-10-04 | Formas amorfas de agentes quelantes e seus métodos de preparação |
PT115056 | 2018-10-04 | ||
PCT/GB2019/052799 WO2020070508A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous form of chelating agents and process for preparing them |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220002226A1 true US20220002226A1 (en) | 2022-01-06 |
Family
ID=68296519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/281,732 Pending US20220002226A1 (en) | 2018-10-04 | 2019-10-03 | Amorphous Form of Chelating Agents and Process for Preparing them |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220002226A1 (pt) |
EP (1) | EP3860973A1 (pt) |
JP (1) | JP2022503804A (pt) |
KR (1) | KR20210078503A (pt) |
CN (1) | CN113015718A (pt) |
AU (1) | AU2019354251A1 (pt) |
CA (1) | CA3114278A1 (pt) |
IL (1) | IL281892A (pt) |
PT (1) | PT115056B (pt) |
WO (1) | WO2020070508A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114053859B (zh) * | 2021-11-17 | 2023-08-18 | 重庆科技学院 | 一种硫化氢脱除剂及其制备方法 |
WO2023245463A1 (en) * | 2022-06-21 | 2023-12-28 | L'oreal | A stabilized composition comprising a thiopyridinone compound and chelating agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU797224A1 (ru) * | 1979-04-12 | 1998-02-20 | Институт химической кинетики и горения Сибирского отделения АН СССР | Способ получения винилидендифосфоновой кислоты или ее натриевых солей |
US4636336A (en) * | 1984-11-02 | 1987-01-13 | Rockwell International Corporation | Process for drying a chelating agent |
US4978763A (en) * | 1988-09-27 | 1990-12-18 | Salutar, Inc. | Novel manganese(II) DTPA chelate |
KR100249323B1 (ko) | 1997-12-09 | 2000-03-15 | 이상현 | 고순도 에틸렌디아민4아세트산4나트륨염의 제조방법 |
CN1190413C (zh) * | 2001-12-19 | 2005-02-23 | 钟林 | 乙二胺四乙酸络合金属盐的生产方法 |
EP1891081B1 (en) * | 2005-06-13 | 2014-08-20 | Jubilant Organosys Limited | Process for producing bisphosphonic acids and forms thereof |
WO2010092446A1 (en) * | 2009-01-19 | 2010-08-19 | Orchid Chemicals & Pharmaceuticals Ltd | Pharmaceutical composition comprising cilastatin, a chelating agent and opt. a penem antibiotic |
CN103108643B (zh) * | 2010-01-22 | 2016-10-26 | 希普罗特克有限公司 | 包含过氧化物、醇和螯合剂的抗菌剂 |
CN102229620B (zh) * | 2011-04-27 | 2014-05-28 | 河南清水源科技股份有限公司 | 一种高纯度固体羟基亚乙基二膦酸四钠盐及其生产工艺 |
CN102875400B (zh) * | 2012-09-21 | 2014-08-06 | 万华化学集团股份有限公司 | 一种制备二乙烯三胺五乙酸的方法 |
-
2018
- 2018-10-04 PT PT115056A patent/PT115056B/pt active IP Right Grant
-
2019
- 2019-10-03 US US17/281,732 patent/US20220002226A1/en active Pending
- 2019-10-03 WO PCT/GB2019/052799 patent/WO2020070508A1/en active Search and Examination
- 2019-10-03 JP JP2021516727A patent/JP2022503804A/ja active Pending
- 2019-10-03 EP EP19790705.8A patent/EP3860973A1/en active Pending
- 2019-10-03 KR KR1020217013330A patent/KR20210078503A/ko not_active Application Discontinuation
- 2019-10-03 CN CN201980065426.6A patent/CN113015718A/zh active Pending
- 2019-10-03 CA CA3114278A patent/CA3114278A1/en active Pending
- 2019-10-03 AU AU2019354251A patent/AU2019354251A1/en active Pending
-
2021
- 2021-03-29 IL IL281892A patent/IL281892A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3860973A1 (en) | 2021-08-11 |
AU2019354251A1 (en) | 2021-04-15 |
WO2020070508A1 (en) | 2020-04-09 |
CA3114278A1 (en) | 2020-04-09 |
CN113015718A (zh) | 2021-06-22 |
PT115056A (pt) | 2020-07-24 |
PT115056B (pt) | 2021-12-10 |
JP2022503804A (ja) | 2022-01-12 |
KR20210078503A (ko) | 2021-06-28 |
IL281892A (en) | 2021-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220002226A1 (en) | Amorphous Form of Chelating Agents and Process for Preparing them | |
JP6499187B2 (ja) | 支援された粒子径低減方法 | |
US9376649B2 (en) | Method for producing a crystalline solid from glycine-N,N-diacetic acid derivatives with sufficiently reduced hygroscopicity | |
EP2326307B1 (de) | Verfahren zur herstellung kristalliner wirkstoff-mikropartikel | |
US7358093B2 (en) | Aztreonam L-lysine and methods for the preparation and analysis thereof | |
US20080280858A1 (en) | Method of creating crystalline substances | |
CN104854079A (zh) | 谷氨酸n,n-二乙酸的盐的结晶颗粒 | |
US10793521B2 (en) | Crystalline form II of dextral oxiracetam, preparation method therefor and use thereof | |
WO2017001991A1 (en) | Cocrystals of trigonelline | |
CN110876259A (zh) | 注射用组合物 | |
US20090306029A1 (en) | Process for the preparation of sterile powdered pharmaceutical compounds | |
US20120135965A1 (en) | Amorphous fosamprenavir calcium | |
CN104854078A (zh) | 谷氨酸n,n-二乙酸的结晶颗粒 | |
US20160228583A1 (en) | Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form | |
WO2007064595A2 (en) | Fluocinolone acetonide drug substance polymorphic interconversion | |
CN102234304A (zh) | 一种熊果酸盐、其制备方法及其晶体 | |
EP3149014B1 (de) | Verfahren zur herstellung kristalliner dtpmp | |
Stahl et al. | Alternative Solid Forms: Salts | |
DD260279A5 (de) | Verfahren zur herstellung heterocyclischer verbindungen mit einem 2-(2-[n,n-bis-12)2-chlorethyl)-diamido-phosphoryloxy]ethyl)-rest | |
WO2021052768A1 (de) | Phosphonsäurederivate und verfahren zu deren herstellung | |
Kumar et al. | Improved hydrosolubility and rate of dissolution of famotidine by hydrotropism | |
CN114369136A (zh) | 一种Lupane三萜系衍生物的碱加成盐及其应用 | |
CN107987043A (zh) | 一种吗替麦考酚酯新晶型 | |
US20120121708A1 (en) | Acetazolamide Microparticle And Its Preparation Method And Use | |
JPS59106464A (ja) | ビタミンb↓6塩酸塩微細晶の製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOVIONE SCIENTIA LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SALDANHA, SUSANA;PARREIRA, ANTONIO;SEQUEIRA, SARA;AND OTHERS;SIGNING DATES FROM 20210429 TO 20210430;REEL/FRAME:056231/0700 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |